156 related articles for article (PubMed ID: 11208402)
1. 2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia--the analysis of own experience and the review of literature.
Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Hellmann A
Med Sci Monit; 2000; 6(4):740-5. PubMed ID: 11208402
[TBL] [Abstract][Full Text] [Related]
2. 2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia.
Delannoy A; Ferrant A; Martiat P; Bosly A; Zenebergh A; Michaux JL
Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):317-20. PubMed ID: 7971252
[TBL] [Abstract][Full Text] [Related]
3. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
[TBL] [Abstract][Full Text] [Related]
4. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia.
Hellmann A; Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Robak T
Eur J Haematol; 1999 Jul; 63(1):35-41. PubMed ID: 10414453
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.
Lewandowski K; Halaburda K; Hellmann A
Leuk Lymphoma; 2002 Feb; 43(2):361-3. PubMed ID: 11999570
[TBL] [Abstract][Full Text] [Related]
6. Marked increase in serum IgM during treatment of Waldenstrom's macroglobulinemia with cladribine.
Krishna VM; Carey RW; Bloch KJ
N Engl J Med; 2003 May; 348(20):2045-6. PubMed ID: 12748329
[No Abstract] [Full Text] [Related]
7. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
8. Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?
Ling S; Joshua DE; Gibson J; Young G; Iland H; Watson G; Ho PJ
Am J Hematol; 2006 Feb; 81(2):110-4. PubMed ID: 16432856
[TBL] [Abstract][Full Text] [Related]
9. 2-Chloro-2'-deoxyadenosine (2-CdA) treatment in a patient with Waldenström's macroglobulinaemia complicated by severe neutrocytopenia.
Zaucha JM; Ciesielski D; Grieb P; Hellmann A
Arch Immunol Ther Exp (Warsz); 1994; 42(1):35-7. PubMed ID: 7503632
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine therapy in a patient with progressive symptomatic Waldenström's macroglobulinemia.
Hałaburda K; Hellmann A
Acta Haematol Pol; 1994; 25(1):63-7. PubMed ID: 8209618
[TBL] [Abstract][Full Text] [Related]
11. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.
Delannoy A; Ferrant A; Martiat P; Montfort L; Doyen C; Sokal G; Michaux JL
Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):311-5. PubMed ID: 7971251
[TBL] [Abstract][Full Text] [Related]
12. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK).
Betticher DC; Hsu Schmitz SF; Ratschiller D; von Rohr A; Egger T; Pugin P; Stalder M; Hess U; Fey MF; Cerny T
Br J Haematol; 1997 Nov; 99(2):358-63. PubMed ID: 9375754
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Dimopoulos MA; O'Brien S; Kantarjian H; Estey EE; Keating MJ; Alexanian R
Leuk Lymphoma; 1993; 11 Suppl 2():105-8. PubMed ID: 7907250
[TBL] [Abstract][Full Text] [Related]
14. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.
Dimopoulos MA; Kantarjian H; Weber D; O'Brien S; Estey E; Delasalle K; Rose E; Cabanillas F; Keating M; Alexanian R
J Clin Oncol; 1994 Dec; 12(12):2694-8. PubMed ID: 7989946
[TBL] [Abstract][Full Text] [Related]
15. Early-onset autoimmune hemolytic anemia after cladribine therapy for Waldenström's macroglobulinemia.
Aslan DL; Peterson BA; Long-Tsai M; Eastlund T
Transfusion; 2006 Jan; 46(1):90-4. PubMed ID: 16398735
[TBL] [Abstract][Full Text] [Related]
16. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
Treon SP; Hunter ZR; Matous J; Joyce RM; Mannion B; Advani R; Cook D; Songer J; Hill J; Kaden BR; Sharon D; Steiss R; Leleu X; Branagan AR; Badros A
Clin Cancer Res; 2007 Jun; 13(11):3320-5. PubMed ID: 17545538
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of Waldenström's disease with cladribine. Arbeitsgemeinschaft Medikamentöse Tumortherapie.
Fridrik MA; Jäger G; Baldinger C; Krieger O; Chott A; Bettelheim P
Ann Hematol; 1997 Jan; 74(1):7-10. PubMed ID: 9031608
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors.
Dimopoulos MA; Weber D; Delasalle KB; Keating M; Alexanian R
Ann Oncol; 1995 Jan; 6(1):49-52. PubMed ID: 7710983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
